Zhejiang Hisun Pharmaceutical Co., Ltd. Provided earnings guidance for the year 2017. For the year, the company expected losses into gains in the net profit belonging to shareholders of the listed company in 2017, with the net profit belonging to shareholders of the listed company to be between RMB10 million and RMB 15 million compared with RMB 94.43 million at the same period of the year before. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 130 million and RMB 120 million.